Kanneboyina Nagaraju

Kanneboyina Nagaraju
Kanneboyina Nagaraju
Born	India
Title	Dean and SUNY Distinguished Professor
Academic background
Education	Sri Venkateswara Veterinary University Indian Veterinary Research Institute Sanjay Gandhi Postgraduate Institute of Medical Sciences
Academic work
Institutions	National Institute of Health Johns Hopkins University School of Medicine Children's National Medical Center George Washington University School of Medicine; Binghamton University

Kanneboyina Nagaraju is the Dean of the School of Pharmacy and Pharmaceutical Sciences at the State University of New York (SUNY), Binghamton. He holds the prestigious title of SUNY Distinguished Professor, the highest faculty rank awarded by the State University of New York system.

Nagaraju is a renowned medical scientist and immunologist, known for developing the MHC Class I transgenic mouse model for autoimmune myositis.^[1] He played a pivotal role in the identification and development of Vamorolone (AGAMREE), a potent anti-inflammatory and membrane-stabilizing dissociated glucocorticoid with fewer side effects, in collaboration with Eric Hoffman and John McCall. Vamorolone has been approved by the Food and Drug Administration, the European Medicines Agency, and the Medicines and Healthcare Products Regulatory Agency for the treatment of children with Duchenne Muscular Dystrophy. Additionally, Nagaraju has led global initiatives to improve the rigor and reproducibility of preclinical drug trials and phenotyping in neuromuscular disease models.^[2]^[3]^[4]

Education and career[edit]

Nagaraju began his academic journey with veterinary training at Sri Venkateswara Veterinary University and the Indian Veterinary Research Institute. He then pursued a PhD in Immunology at the Sanjay Gandhi Postgraduate Institute of Medical Sciences and completed postdoctoral training in immunology at the National Institutes of Health (NIH). His academic career includes tenure-track and tenured positions at Johns Hopkins University School of Medicine, Children's National Medical Center, and George Washington University School of Medicine. At SUNY Binghamton, he is a Professor of Pharmaceutical Sciences and the Founding Chair of the Department of Pharmaceutical Sciences. He has also served as Vice Dean of the School of Pharmacy and Pharmaceutical Sciences.

Beyond academia, Nagaraju is an accomplished entrepreneur, co-founding ReveraGen BioPharma, which develops Vamorolone for inflammatory diseases, including muscular dystrophy, and AGADA BioSciences, which provides preclinical and clinical trial support services for therapeutics targeting rare neuromuscular diseases.

References[edit]

^ Nagaraju, K.; Raben, N.; Loeffler, L.; Parker, T.; Rochon, P. J.; Lee, E.; Danning, C.; Wada, R.; Thompson, C. (1 August 2000). "Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies". Proceedings of the National Academy of Sciences of the United States of America. 97 (16): 9209–9214. doi:10.1073/pnas.97.16.9209. ISSN 0027-8424. PMC 16847. PMID 10922072.
^ Willmann, Raffaella; De Luca, Annamaria; Benatar, Michael; Grounds, Miranda; Dubach, Judith; Raymackers, Jean-Marc; Nagaraju, Kanneboyina; TREAT-NMD Neuromuscular Network (January 2012). "Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice". Neuromuscular Disorders. 22 (1): 43–49. doi:10.1016/j.nmd.2011.04.012. ISSN 1873-2364. PMC 3227750. PMID 21737275.
^ Willmann, Raffaella; Luca, Annamaria De; Nagaraju, Kanneboyina; Rüegg, Markus A. (14 May 2015). "Best Practices and Standard Protocols as a Tool to Enhance Translation for Neuromuscular Disorders" (PDF). Journal of Neuromuscular Diseases. 2 (2): 113–117. doi:10.3233/jnd-140067. ISSN 2214-3599. PMID 27858730.
^ Gordish-Dressman, Heather; Willmann, Raffaella; Dalle Pazze, Laura; Kreibich, Arati; van Putten, Maaike; Heydemann, Ahlke; Bogdanik, Laurent; Lutz, Cathleen; Davies, Kay (2018). ""Of Mice and Measures": A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic". Journal of Neuromuscular Diseases. 5 (4): 407–417. doi:10.3233/JND-180324. ISSN 2214-3599. PMC 6218134. PMID 30198876.

External links[edit]

At Google Scholar

[1] Nagaraju, K.; Raben, N.; Loeffler, L.; Parker, T.; Rochon, P. J.; Lee, E.; Danning, C.; Wada, R.; Thompson, C. (1 August 2000). "Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies". Proceedings of the National Academy of Sciences of the United States of America. 97 (16): 9209–9214. doi:10.1073/pnas.97.16.9209. ISSN 0027-8424. PMC 16847. PMID 10922072.

[2] Willmann, Raffaella; De Luca, Annamaria; Benatar, Michael; Grounds, Miranda; Dubach, Judith; Raymackers, Jean-Marc; Nagaraju, Kanneboyina; TREAT-NMD Neuromuscular Network (January 2012). "Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice". Neuromuscular Disorders. 22 (1): 43–49. doi:10.1016/j.nmd.2011.04.012. ISSN 1873-2364. PMC 3227750. PMID 21737275.

[3] Willmann, Raffaella; Luca, Annamaria De; Nagaraju, Kanneboyina; Rüegg, Markus A. (14 May 2015). "Best Practices and Standard Protocols as a Tool to Enhance Translation for Neuromuscular Disorders" (PDF). Journal of Neuromuscular Diseases. 2 (2): 113–117. doi:10.3233/jnd-140067. ISSN 2214-3599. PMID 27858730.

[4] Gordish-Dressman, Heather; Willmann, Raffaella; Dalle Pazze, Laura; Kreibich, Arati; van Putten, Maaike; Heydemann, Ahlke; Bogdanik, Laurent; Lutz, Cathleen; Davies, Kay (2018). ""Of Mice and Measures": A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic". Journal of Neuromuscular Diseases. 5 (4): 407–417. doi:10.3233/JND-180324. ISSN 2214-3599. PMC 6218134. PMID 30198876.

[1]

[2]

[3]

[4]